- Home
- NRSN
as 11-14-2024 12:36pm EST
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
| Founded: | 2017 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 26.3M | IPO Year: | 2021 |
| Target Price: | N/A | AVG Volume (30 days): | 181.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.47 - $2.33 | Next Earning Date: | 11-26-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest NeuroSense Therapeutics Ltd. News
NRSN Breaking Stock News: Dive into NRSN Ticker-Specific Updates for Smart Investing
MT Newswires
17 days ago
Neurosense, FDA to Meet Nov. 6 to Discuss Design of Amyotrophic Lateral Sclerosis Treatment Trial; Shares Rise
PR Newswire
18 days ago
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission
Benzinga
18 days ago
EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission
PR Newswire
22 days ago
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients
PR Newswire
a month ago
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates
MT Newswires
a month ago
NeuroSense Therapeutics Seeking Early Regulatory Approval for Prospective ALS Treatment in Canada
PR Newswire
a month ago
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
PR Newswire
a month ago
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting
Compare NRSN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NRSN NeuroSense Therapeutics Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.